Eterna Therapeutics' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101
Eterna said the proof-of-concept study demonstrated "massive" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.
By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 "may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future," the company said.
Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.
Price: 0.4959, Change: +0.19, Percent Change: +60.49
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。